PRR11-positive expression was observed in 93.0% esophageal primary tumors, 64.6% gastric tumors, 64.5% colorectal tumors, 87.7% pancreatic ductal carcinomas, 53.3% hepatocellular carcinomas and 63.3% hilar cholangiocarcinoma (Figure 1B). This evidence concerns the gene PRR11 and hepatocellular carcinoma.